The patient should be informed that if flu-like symptoms or malaise occurs, the physician should be notified immediately.
ERGAMISOL® (levamisole hydrochloride) has been reported to produce "ANTABUSE"-like side effects when given concomitantly with alcohol. Concomitant administration of phenytoin and ERGAMISOL® plus fluorouracil has lead to increased plasma levels of phenytoin. The physician is advised to monitor plasma levels of phenytoin and to decrease the dose if necessary.
Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.
ERGAMISOL® (levamisole hydrochloride) is contraindicated in patients with a known hypersensitivity to the drug or its components.